Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia

Jithma P. Abeykoon, Saurabh Zanwar, Stephen M. Ansell, Eli Muchtar, Rong He, Patricia T. Greipp, Rebecca L. King, Sikander Ailawadhi, Jonas Paludo, Jeremy T. Larsen, Thomas M. Habermann, David Inwards, Ronald S. Go, Gita Thanarajasingam, Francis Buadi, Angela Dispenzieri, Carrie A. Thompson, Thomas E. Witzig, Martha Lacy, Wilson GonsalvesGrzegorz S. Nowakowski, David Dingli, Sundararajan Vincent Rajkumar, Robert A. Kyle, Taimur Sher, Vivek Roy, Allison Rosenthal, Asher A. Chanan-Khan, Craig Reeder, Morie A. Gertz, Shaji Kumar, Prashant Kapoor

Research output: Contribution to journalArticlepeer-review


Comparative data guiding initial therapy for Waldenström macroglobulinemia (WM), an infrequently encountered non-Hodgkin lymphoma, are sparse. We evaluated three commonly used rituximab-based frontline regimens: rituximab-bendamustine (R-Benda); dexamethasone, rituximab, cyclophosphamide (DRC); and bortezomib, dexamethasone, rituximab (BDR) in 220 treatment-naïve patients with WM, seen at Mayo Clinic between November 1, 2000 and October 31, 2019. The median follow-up was 4.5 (95%CI: 4–5) years. The R-Benda cohort (n = 83) demonstrated superior overall response rate (ORR: 98%), in comparison to DRC (n = 92, ORR: 78%) or BDR (n = 45, ORR: 84%) cohorts, p = 0.003. Similarly, longer progression-free survival (PFS) was evident with R-Benda use [median 5.2 vs. 4.3 (DRC) and 1.8 years (BDR), p < 0.001]. The time-to-next therapy (TTNT) favored R-Benda [median, not-reached, 4.4 (DRC) and 2.6 years (BDR), p < 0.001). These endpoints were comparable between the DRC and BDR cohorts. Overall survival (OS) was similar across the three cohorts, p = 0.77. In a subset analysis of 142 patients genotyped for MYD88L265P mutation, the ORR, PFS and TTNT were unaffected by the patients' MYD88 signature within each cohort. In conclusion, ORR, PFS and TTNT with R-Benda are superior compared to DRC or BDR in treatment-naïve patients with active WM. The patient outcomes with any one of these three regimens are unaffected by the MYD88L265P mutation status.

Original languageEnglish (US)
Pages (from-to)945-953
Number of pages9
JournalAmerican journal of hematology
Issue number8
StatePublished - Aug 1 2021

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia'. Together they form a unique fingerprint.

Cite this